BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23252601)

  • 1. Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy).
    Razzaboni E; Toss A; Cortesi L; Marchi I; Sebastiani F; De Matteis E; Federico M
    Breast J; 2013; 19(1):10-21. PubMed ID: 23252601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
    Loehberg CR; Jud SM; Haeberle L; Heusinger K; Dilbat G; Hein A; Rauh C; Dall P; Rix N; Heinrich S; Buchholz S; Lex B; Reichler B; Adamietz B; Schulz-Wendtland R; Beckmann MW; Fasching PA
    Breast Cancer Res Treat; 2010 May; 121(1):101-10. PubMed ID: 20306293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Women's views on chemoprevention of breast cancer: qualitative study.
    Heisey R; Pimlott N; Clemons M; Cummings S; Drummond N
    Can Fam Physician; 2006 May; 52(5):624-5. PubMed ID: 17327893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
    Fabian CJ; Kimler BF; Zalles CM; Khan QJ; Mayo MS; Phillips TA; Simonsen M; Metheny T; Petroff BK
    Breast Cancer Res Treat; 2007 Nov; 106(1):75-84. PubMed ID: 17221152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
    Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial.
    Kinney AY; Richards C; Vernon SW; Vogel VG
    Prev Med; 1998; 27(5 Pt 1):713-9. PubMed ID: 9808803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
    Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
    J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
    Kyvernitakis I; Ziller V; Hars O; Bauer M; Kalder M; Hadji P
    Climacteric; 2014 Jun; 17(3):252-9. PubMed ID: 23805799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.
    Roetzheim RG; Lee JH; Fulp W; Matos Gomez E; Clayton E; Tollin S; Khakpour N; Laronga C; Lee MC; Kiluk JV
    Breast; 2015 Feb; 24(1):51-6. PubMed ID: 25491191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
    Chino A; Okamoto H; Hirasaki Y; Ueda K; Ogawa K; Namiki T
    J Altern Complement Med; 2011 Nov; 17(11):1075-7. PubMed ID: 22070441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
    Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
    J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer chemoprevention - a vision not yet realized.
    Blaha P; Dubsky P; Fitzal F; Bachleitner-Hofmann T; Jakesz R; Gnant M; Steger G
    Eur J Cancer Care (Engl); 2009 Sep; 18(5):438-46. PubMed ID: 19686352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.
    Taylor R; Taguchi K
    Ann Fam Med; 2005; 3(3):242-7. PubMed ID: 15928228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of and satisfaction with bilateral prophylactic mastectomy.
    Stefanek ME; Helzlsouer KJ; Wilcox PM; Houn F
    Prev Med; 1995 Jul; 24(4):412-9. PubMed ID: 7479633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.